Synlogic (SYBX) Competitors $1.44 +0.08 (+5.86%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SYBX vs. CTMX, ALVR, LPTX, BYSI, SPRO, ALXO, IMRX, ALGS, MGX, and INCRShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include CytomX Therapeutics (CTMX), AlloVir (ALVR), Leap Therapeutics (LPTX), BeyondSpring (BYSI), Spero Therapeutics (SPRO), ALX Oncology (ALXO), Immuneering (IMRX), Aligos Therapeutics (ALGS), Metagenomi (MGX), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. CytomX Therapeutics AlloVir Leap Therapeutics BeyondSpring Spero Therapeutics ALX Oncology Immuneering Aligos Therapeutics Metagenomi InterCure Synlogic (NASDAQ:SYBX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Does the media favor SYBX or CTMX? In the previous week, CytomX Therapeutics had 2 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.00 beat CytomX Therapeutics' score of 0.70 indicating that Synlogic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SYBX or CTMX more profitable? CytomX Therapeutics has a net margin of 10.96% compared to Synlogic's net margin of -2,284.65%. CytomX Therapeutics' return on equity of -41.47% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets Synlogic-2,284.65% -207.84% -114.81% CytomX Therapeutics 10.96%-41.47%8.11% Which has more risk & volatility, SYBX or CTMX? Synlogic has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Do insiders & institutionals believe in SYBX or CTMX? 63.4% of Synlogic shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 3.0% of Synlogic shares are held by company insiders. Comparatively, 7.0% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, SYBX or CTMX? CytomX Therapeutics has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$3.37M5.02-$57.28M-$4.16-0.35CytomX Therapeutics$101.21M0.65-$570K$0.174.98 Does the MarketBeat Community prefer SYBX or CTMX? CytomX Therapeutics received 41 more outperform votes than Synlogic when rated by MarketBeat users. However, 69.54% of users gave Synlogic an outperform vote while only 65.49% of users gave CytomX Therapeutics an outperform vote. CompanyUnderperformOutperformSynlogicOutperform Votes33169.54% Underperform Votes14530.46% CytomX TherapeuticsOutperform Votes37265.49% Underperform Votes19634.51% Do analysts recommend SYBX or CTMX? Synlogic presently has a consensus target price of $30.00, indicating a potential upside of 1,976.41%. CytomX Therapeutics has a consensus target price of $5.77, indicating a potential upside of 581.85%. Given Synlogic's higher possible upside, research analysts plainly believe Synlogic is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20CytomX Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryCytomX Therapeutics beats Synlogic on 14 of the 18 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.90M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.354.9789.5613.60Price / Sales5.02371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book1.2910.306.976.33Net Income-$57.28M$153.61M$119.04M$225.93M7 Day Performance3.94%-1.73%-1.78%-0.96%1 Month Performance0.33%-7.26%-3.59%1.06%1 Year Performance-31.85%31.10%31.64%26.59% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic3.1006 of 5 stars$1.44+5.9%$30.00+1,976.4%-30.5%$16.90M$3.37M-0.356Positive NewsGap UpCTMXCytomX Therapeutics4.3829 of 5 stars$0.85-2.7%$5.77+581.8%-37.4%$66.26M$101.21M5.12170Short Interest ↓ALVRAlloVir2.6268 of 5 stars$0.57+0.6%N/A-65.2%$66.24MN/A0.00110Positive NewsLPTXLeap Therapeutics2.4038 of 5 stars$2.58-0.4%$7.50+190.7%+25.1%$66.05M$1.50M0.0040Positive NewsBYSIBeyondSpringN/A$1.68-1.8%N/A+86.1%$65.57M$1.75M0.0080SPROSpero Therapeutics4.5933 of 5 stars$1.20flat$5.00+316.7%-2.4%$65.42M$103.78M17.1546Analyst ForecastALXOALX Oncology3.3343 of 5 stars$1.22+0.8%$12.50+924.6%-87.7%$64.34MN/A0.0040IMRXImmuneering2.8292 of 5 stars$2.07+1.5%$12.80+518.4%-63.4%$64.27M$320,000.000.0060Analyst ForecastALGSAligos Therapeutics4.1561 of 5 stars$17.70-2.7%$75.00+323.7%+5.5%$63.54M$15.53M-1.3790MGXMetagenomi3.1701 of 5 stars$1.67+1.2%$15.50+828.1%N/A$62.49M$44.76M0.00236Analyst ForecastINCRInterCure1.2529 of 5 stars$1.36+2.0%N/A+16.0%$61.98M$96.61M0.00350Positive News Related Companies and Tools Related Companies CytomX Therapeutics Competitors AlloVir Competitors Leap Therapeutics Competitors BeyondSpring Competitors Spero Therapeutics Competitors ALX Oncology Competitors Immuneering Competitors Aligos Therapeutics Competitors Metagenomi Competitors InterCure Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SYBX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
